Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118086 · ClinicalTrials.gov registry record · Phase 1
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
A Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, sponsored by Remix Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT06118086 is a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma that is actively recruiting participants, run by Remix Therapeutics. The registered enrollment target is 100 participants, below the 122-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (18% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT06118086, a Phase 1 study of Adenoid Cystic Carcinoma and Metastatic Adenoid Cystic Carcinoma, is actively recruiting participants, sponsored by Remix Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
Conditions Studied
Interventions
- DRUG REM-422
Study Locations (8)
Other
- Centre Antoine Lacassagne - Nice
- Institut de Cancerologie Gustave-Roussy - Villejuif
California
- University of California San Francisco Helen Diller Comprehensive Cancer Center - San Francisco
Massachusetts
- Dana Farber Cancer Research Institute - Boston
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06118086
The ClinicalTrials.gov registry entry for NCT06118086 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 122-participant average among 16 other Adenoid Cystic Carcinoma trials with a reported enrollment target (18% lower). The listed sponsor is Remix Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Adenoid Cystic Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which REM-422 is the first listed.
NCT06118086 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06118086 about?
NCT06118086 is a clinical study titled "Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma". The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)
What is the current status of trial NCT06118086?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2023-12-20. Estimated completion is 2027-06-01.
What conditions does trial NCT06118086 study?
This clinical trial studies the following conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma.
What interventions are being tested in trial NCT06118086?
The interventions under investigation include: REM-422 (DRUG).
Who is sponsoring clinical trial NCT06118086?
This trial is sponsored by Remix Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118086 being conducted?
This trial has 8 study locations across California, Massachusetts, Michigan, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoid Cystic Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
RECRUITING · Phase 1
-
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
RECRUITING · Phase 1
-
A Study of XMT-1660 in Participants With Solid Tumors
RECRUITING · Phase 1
-
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Adenoid Cystic Carcinoma
All registered trials for this condition
Metastatic Adenoid Cystic Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.